Venous Leg Ulcer - A Pipeline Analysis Report

Overview of the drug development pipeline for venous leg ulcer

A venous leg ulcer is a type of ulcer that occurs when the veins in the legs fail to push blood back to the heart as effectively as they should. Blood backs up in the veins and starts building up the pressure. If not treated, increased pressure and excess fluid in the affected area can cause an open sore. The primary symptoms of venous leg ulcer include pain, itching, and swelling in the affected leg. Also, there may be discolored or hardened skin around the ulcer and the sore may produce a foul-smelling discharge. A venous leg ulcer is the most common form of leg ulcers, accounting for over 60 to 80 percent of all leg ulcers. On an average, 33 to 60 percent of venous leg ulcers persist for more than six weeks and are therefore referred to as chronic venous leg ulcers. These ulcers create a significant clinical problem, affecting approximately 1% of the population and 3% of the people over 80 years of age in Western countries such as the US, Canada, European Union countries, Australia, and New Zealand. Moreover, with people living longer often with multiple comorbidities such as arthritis, DVT, or varicose veins, the global prevalence of venous leg ulcer is expected to escalate dramatically, in turn, promoting the drug development for venous leg ulcer in the forthcoming years.

According to this pipeline analysis report, most of the gene therapy molecules in the pipeline are being developed for the treatment of venous leg ulcer. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the drug development of for the treatment of venous leg ulcer. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the gene therapy molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Factor Therapeutics
• FirstString Research
• CytoTools
• MediWound

Therapeutic assessment of the drug development pipeline for venous leg ulcer by route of administration

• Topical
• Oral
• Intralesional

The topical route of administration (ROA) involves the application of the drug directly on the surface of the skin, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for venous leg ulcer by therapy

• Monotherapy
• Undisclosed

According to this pipeline analysis report, all the molecules that are currently in the drug development pipeline for venous leg ulcer are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug development molecules in the various development stages for venous leg ulcer?
• What are the companies that are currently involved in the development of drug development molecules for venous leg ulcer?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.